Skip to main content

Table 1 Patient demographic and primary invasive tumor characteristics among cases in WCHS, 2001–2017

From: Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women

 

Black

White

Overall

Overall

N

550 (79.9%)

138 (20.1%)

688 (100%)

Age at diagnosis

Median/IQR

55.0/(46, 62)

52.5/(45, 60)

54.5/(46, 61)

Subtype

Luminal A

322 (59.3%)

91 (65.9%)

413 (60.6%)

HER2-positive

80 (14.7%)

28 (20.3%)

108 (15.9%)

Triple-negative

141 (26.0%)

19 (13.8%)

160 (23.5%)

ER

Positive

366 (66.7%)

107 (77.5%)

473 (68.9%)

Negative

183 (33.3%)

31 (22.5%)

214 (31.1%)

PR

Positive

284 (52.1%)

82 (59.4%)

366 (53.6%)

Negative

261 (47.9%)

56 (40.6%)

317 (46.4%)

HER2

Positive

80 (14.7%)

28 (20.3%)

108 (15.8%)

Negative

464 (85.3%)

110 (79.7%)

574 (84.2%)

Stage

I

221 (40.2%)

62 (45.3%)

283 (41.2%)

II

250 (45.5%)

57 (41.6%)

307 (44.7%)

III/IV

79 (14.4%)

18 (13.1%)

97 (14.1%)

Grade

Low

69 (12.6%)

29 (21.5%)

98 (14.4%)

Intermediate

186 (34.1%)

60 (44.4%)

246 (36.1%)

High

291 (53.3%)

46 (34.1%)

337 (49.5%)

Tumor size

< 1.0

54 (9.9%)

21 (15.3%)

75 (11.0%)

1–1.9

199 (36.4%)

54 (39.4%)

253 (37.0%)

≥ 2.0

294 (53.7%)

62 (45.3%)

356 (52.0%)

LN status

Positive

221 (41.2%)

51 (37.5%)

272 (40.4%)

Negative

316 (58.8%)

85 (62.5%)

401 (59.6%)

OS

10-year rate

0.78

0.87

0.81

95% CI

0.72–0.84

0.79–0.92

0.76–0.85

DSS

10-year rate

0.84

0.92

0.87

95% CI

0.78–0.89

0.84–0.96

0.82–0.90

  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2. Four staging categories, I–IV, from the American Joint Committee on Cancer (AJCC) were examined; stage 0 patients were not included in this study. Low tumor grade denotes well-differentiated tumors, intermediate denotes moderately differentiated, and high grade denotes poorly differentiated tumors. Tumor size (cm) was classified into three categories: < 1.0 cm, 1.0–2.0 cm, and > 2.0 cm. Lymph node (LN) status was defined as the presence (positive) or no (negative) cancer cells in the axillary lymph nodes